Showing results (241-250 of 292) with videos related to
Sort By:
Pageof 30
Expert Review of Pharmacoeconomics & Outcomes Research|November 16, 2023
Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countriesZoltán Kaló, Maciej Niewada, Tamás Bereczky, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 29, 2023
A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group ReportEvelien Moorkens, Teresa Barcina Lacosta, Dalia Dawoud, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 14, 2018
Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest GroupSandra Nestler-Parr, Daria Korchagina, Mondher Toumi, et al.Health Policy (Amsterdam, Netherlands)|January 15, 2008
Reforming the Belgian market for orthotic braces: what can we learn from the international experience?Steven Simoens, Sandra De Coster, Ingrid Moldenaers, et al.Journal of Market Access & Health Policy|November 19, 2016
Determining the value of medical technologies to treat ultra-rare disorders: a consensus statementMichael Schlander, Silvio Garattini, Peter Kolominsky-Rabas, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|June 4, 2008
International comparison of orthotic brace pricesSteven Simoens, Paul Guillaume, Ingrid Moldenaers, et al.Drug Discovery Today|September 30, 2018
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature reviewEline van Overbeeke, Chiara Whichello, Rosanne Janssens, et al.The Journal of Antimicrobial Chemotherapy|September 20, 2011
Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementationPieter-Jan Cortoos, Christa Gilissen, Peter G M Mol, et al.Pharmacoeconomics|September 14, 2013
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare settingJoris Kleintjens, Xiao Li, Steven Simoens, et al.Orphanet Journal of Rare Diseases|March 11, 2025
Caregivers and multidisciplinary team members' perspectives on shared decision making in Duchenne muscular dystrophy: A qualitative studyElise Schoefs, Thomas Desmet, Evelyn Lerinckx, et al.Pageof 30